Mode
Text Size
Log in / Sign up
Phase 4 N=150 Randomized Triple-blind Treatment

Ketamine Infusion Therapy for the Management of Acute Pain in Adult Rib Fracture Patients

Wounds and Injuries · Rib Fractures

Enrolled (actual)
150
Serious AEs
0.0%
Results posted
Feb 2020
Primary outcome: Primary: Visual Analog Numeric Pain Score — 6.1; 5.7; 5.2; 5.1 score on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Ketamine (Drug); Placebo (Drug); Intercostal Nerve Block (Procedure); Acetaminophen (Drug); Ibuprofen (Drug); Pantoprazole (Drug); Methocarbamol (Drug); Opioid (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Medical College of Wisconsin
Primary completion
Aug 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Visual Analog Numeric Pain Score
5.8; 5.6; 4.4; 5.1
SECONDARY
Visual Analog Numeric Pain Score
5.8; 5.6; 4.4; 5.1
SECONDARY
Oral Morphine Equivalent (Narcotic Usage)
67; 69.0; 44; 25
SECONDARY
Oral Morphine Equivalent (Narcotic Usage)
67; 69.0; 44; 25
SECONDARY
Length of Stay
4.0; 5; 6; 5
SECONDARY
Regional Anesthesia Utilization
3; 7; 6; 4
SECONDARY
Respiratory Failure
3; 2; 0; 0
SECONDARY
Hallucination
1; 0; 2; 2
SECONDARY
Oral Morphine Equivalent (Narcotic Usage) in Severely Injured
170.5; 153.0; 86.8; 67.5

Summary

This study will evaluate the effectiveness of ketamine infusions in the management of acute pain resulting from broken ribs suffered following a blunt trauma. Half of patients will receive the institutional standard of care and a placebo infusion (no active medication). The other half of patients will receive the institutional standard of care and a ketamine infusion. All subjects and staff will be blinded as to whether they are receiving placebo or ketamine.

Eligibility Criteria

Inclusion Criteria

  • age greater than 18 years
  • rib fractures following recent trauma with admission to Froedtert Memorial Lutheran Hospital

Exclusion Criteria

  • history of adverse reaction / intolerance to ketamine therapy
  • elevated intracranial pressure
  • ischemic heart disease defined as active acute coronary syndrome
  • severe, poorly controlled hypertension (Systolic Blood Pressure > 200 mmHg or Diastolic Blood Pressure > 100 mmHg)
  • current opiate agonist/antagonist therapy
  • concurrent use of monoamine oxidase inhibitors (MAOIs)
  • chronic pain or opioid tolerance defined as > 3 weeks of >30mg oral morphine equivalents per day
  • current substance abuse with opiates (prescription and/or heroin) or ketamine
  • Glasgow Coma Scale <13
  • Intubation on arrival or need for urgent intubation on arrival
  • inability to delineate pain and/or appropriately communicate with staff
  • history of psychosis
  • three or more psychotropic medications
  • active delirium
  • glaucoma
  • pregnancy
  • prisoners
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02432456). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search